Table 2.
Treatments and outcomes for 72 patients with COVID-19.
| Total (n = 72) | Corticosteroids treated (n = 28) | Corticosteroids untreated (n = 44) | p-value | |
|---|---|---|---|---|
| Treatments | ||||
| Aerosol interferon-alpha | 72 (100%) | 28 (100%) | 44 (100%) | … |
| Arbidol | 37 (51.4%) | 15 (53.6%) | 22 (50.0%) | 0.768 |
| Lopinavir/ritonavir or darunavir/cobicistat | 66 (91.7%) | 27 (96.4%) | 39 (88.6%) | 0.466 |
| Intravenous immunoglobulin | 40 (55.5%) | 28 (100%) | 12 (27.3%) | <0.001 |
| Antibiotics | 15 (20.8%) | 11 (39.3%) | 4 (9.1%) | 0.002 |
| High-flow nasal cannula oxygen therapy | 0 (0%) | 0 (0%) | 0 (0%) | … |
| Mechanical ventilation | 0 (0%) | 0 (0%) | 0 (0%) | … |
| Outcomes | ||||
| Progressed to severe illness | 1 (1.4%) | 1 (3.6%) | 0 (%) | 0.389 |
| Time from illness onset to viral clearance, days | 17.5 (12.3–21) | 18 (14.3–23.5) | 17 (12–20) | 0.252 |
| Hospital stay, days | 20.0 (12.0–27.8) | 25 (16.3–30.0) | 14.5 (10–26) | 0.016 |
| >21 days | 32 (44.4%) | 19 (67.9%) | 13 (29.5%) | 0.001 |
Data were expressed as median (IQR) or n (%). Comparison between groups was done using Mann-Whitney U test, Chi-Square test, or Fisher's exact test, as appropriate.